Treatgut Biotechnology

Xbiome, officially registered as Shenzhen Treatgut Biotechnology, is a leading AI-driven microbiome therapeutics company with headquarters in Shenzhen, China, and research operations in Boston. The company leverages a proprietary artificial intelligence platform to analyze the human gut microbiome and develop targeted therapies, including live biotherapeutic products (LBPs) and standardized fecal microbiota transplantations (FMT). Xbiome's clinical pipeline focuses on high-unmet-need areas such as immunology, oncology, and neurology, with its lead program targeting graft-versus-host disease. Notably, the company was the first in China's microbiome sector to receive IND clearance from the U.S. FDA for an FMT-based drug candidate. By combining high-throughput sequencing with automated laboratory systems, Xbiome aims to accelerate the translation of microbiome research into precision medicine.